期刊文献+

雾化吸入硝酸甘油治疗先天性心脏病合并肺动脉高压的护理观察 被引量:2

Clinical observation of nitroglycerin aerosol inhalation treating congenital heart disease with pulmonary hypertension
下载PDF
导出
摘要 目的:探讨雾化吸入硝酸甘油治疗先天性心脏病合并继发性肺动脉高压的护理观察。方法:将我科2006年6月~2011年6月收治的465例先天性心脏病合并不同程度肺动脉高压的患者随机分为两组,治疗组采用硝酸甘油雾化吸入,对照组采用常规治疗。两组治疗1周后,比较两组患者肺动脉平均压、体外循环后呼吸机辅助时间、术后氧分压(PO2)情况。结果:治疗组肺动脉压控制情况较对照组明显有效,两组比较有统计学差异(P<0.05)。结论:硝酸甘油雾化吸入用于先天性心脏病合并肺动脉高压的干预治疗,能取得较好的治疗效果及预期指标。 Objective: To explore the effect of Nitroglycerin aerosol inhalation treating secondary pulmonary hypertension which by congenital heart disease.Methods Analyse 465 patients who suffered congenital heart disease with pulmonary hypertension from June 2006 to June 2011,randomly divided into two group.Experimental group which treated with nitroglycerin aerosol inhalation,control group which treated with routine therapy.1 week later,Evaluated the quantity of mean pulmonary artery pressure(MPAP),time of assistedrespiration after extracorporeal circulation,PO2 after operation.effective sputum culture results of the two groups patients.Results: Experimental group had significantly controlled PAP than control group.The results was significantly different between two groups(P0.05).Conclusion:The method of nitroglycerin aerosol inhalation treating secondary pulmonary hypertension which by congenital heart disease could get better therapeutic efficacy and anticipative purpose,so that could be applied widely in the clinical practice.
作者 滕莉 耿韫
出处 《护理实践与研究》 2012年第12期49-50,共2页 Nursing Practice and Research
关键词 硝酸甘油 雾化吸入 心脏病 先天性 肺动脉高压 Nitroglycerin Aerosol inhalation Heart disease Congenital Pulmonary hypertension
  • 相关文献

参考文献7

二级参考文献30

  • 1陈树宝.儿科学新理论与新技术[M].上海:上海科技教育出版社,1996.111-112.
  • 2Eddahibi S,Humbert M,Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy [ J]. Am J Respir Crit Care Med,2000,162(4 Pt 1) :1493 - 1499.
  • 3Voelkel NF, Tuder RM. CAlular and molecular mechanisms in the pathogenesis of severe pulmonary hypextemion[J]. Eur Respir J,1995,8(12) :2129- 2138.
  • 4Pmtovian C,Adnot S, Eddshlhi S,et al. Heart and lung VEGF mRNA expression in rots with monocrotaline or hypoxia-induced pulmonary hypertension[J]. Am J Physiol, 1998,275(6 Pt 2) :H1948- 1956.
  • 5Michel JB, Ordway GA, Richardson JA, et al. Biphasic induction of immediate early gene expression accompanies activity-dependent angiogenesis and myofiber remodeling of rabbit skeletal muscle[J]. J Clin Invest, 1994,94(1) : 277 - 285.
  • 6Takaoka S, Faul JL, Doyle R. Current therapies for pulmonary arterial hypertension. Semin Cardiothorac Vasc Anesth, 2007, 11:137-148.
  • 7Barst R J, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 1996, 334:296-302.
  • 8Mclaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482.
  • 9Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007, 93: 739-743.
  • 10Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest, In press 2007.

共引文献73

同被引文献16

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部